New News information at Drug Development Technology New and updated information from News listed on www.drugdevelopment-technology.com http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ New News information at Drug Development Technology http://www.drugdevelopment-technology.com/content/images/logo_big.gif GeoVax begins Phase I trial of GOVX-B11 vaccine to prevent HIV http://www.drugdevelopment-technology.com/news/newsgeovax-begins-clinical-trial-of-govx-b11-vaccine-to-prevent-hiv-5722826 http://www.drugdevelopment-technology.com/news/newsgeovax-begins-clinical-trial-of-govx-b11-vaccine-to-prevent-hiv-5722826 Clinical-stage biotechnology firm GeoVax Labs has initiated the next human Phase I clinical trial (HVTN 114) of its GOVX-B11 vaccine developed to prevent HIV. Tue, 24 Jan 2017 00:00:00 GMT Sanifit begins enrolment in Phase IIb trial of SNF472 to treat cardiovascular calcification http://www.drugdevelopment-technology.com/news/newssanifit-begins-enrollment-in-phase-iib-trial-of-snf472-to-treat-cardiovascular-calcification-5722706 http://www.drugdevelopment-technology.com/news/newssanifit-begins-enrollment-in-phase-iib-trial-of-snf472-to-treat-cardiovascular-calcification-5722706 Clinical-stage biopharmaceutical firm Laboratoris Sanifit has enrolled the first patient in CaLIPSO, a Phase IIb study of SNF472 to treat cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) patients for haemodialysis (HD). Tue, 24 Jan 2017 00:00:00 GMT Infinity reports positive preclinical / Phase I data of IPI-549 for treatment of solid tumours http://www.drugdevelopment-technology.com/news/newsinfinity-presents-preclinicalphase-1-data-of-ipi-549-for-teatment-of-solid-tumors-5722701 http://www.drugdevelopment-technology.com/news/newsinfinity-presents-preclinicalphase-1-data-of-ipi-549-for-teatment-of-solid-tumors-5722701 Infinity Pharmaceuticals has reported positive results from preclinical and Phase I studies of IPI-549 at the Keystone Symposia Conference. Tue, 24 Jan 2017 00:00:00 GMT Boston Biomedical reports positive Phase Ib/II trial results of napabucasin to treat colorectal cancer http://www.drugdevelopment-technology.com/news/newsboston-biomedical-reports-positive-results-of-napabucasin-to-treat-colorectal-cancer-5721622 http://www.drugdevelopment-technology.com/news/newsboston-biomedical-reports-positive-results-of-napabucasin-to-treat-colorectal-cancer-5721622 Boston Biomedical has reported positive data from its Phase Ib/II study of napabucasin to treat metastatic colorectal cancer (mCRC). Mon, 23 Jan 2017 00:00:00 GMT Sobi begins patient enrolment in A-SURE study haemophilia A treatment http://www.drugdevelopment-technology.com/news/newssobi-begins-patient-enrolment-in-a-sure-study-haemophilia-a-treatment-5721880 http://www.drugdevelopment-technology.com/news/newssobi-begins-patient-enrolment-in-a-sure-study-haemophilia-a-treatment-5721880 Swedish Orphan Biovitrum (Sobi) has begun enrolling patients for the A-SURE study, which is designed to evaluate the effectiveness of Elocta compared to conventional FVIII products in the prophylactic treatment of patients with haemophilia A. Mon, 23 Jan 2017 00:00:00 GMT Prima begins dosing patients in Phase IIb trial of IMP321 to teat metastatic breast cancer http://www.drugdevelopment-technology.com/news/newsprima-starts-dosing-patients-in-phase-iib-trial-of-imp321-to-teat-metastatic-breast-cancer-5721895 http://www.drugdevelopment-technology.com/news/newsprima-starts-dosing-patients-in-phase-iib-trial-of-imp321-to-teat-metastatic-breast-cancer-5721895 Global biotechnology firm Prima BioMed has begun dosing patients in a Phase IIb clinical trial of its antigen presenting cell (APC) activator, IMP321, for the treatment of metastatic breast cancer. Mon, 23 Jan 2017 00:00:00 GMT Daiichi Sankyo begins Phase I/II trial of U3-1402 to treat breast cancer in Japan http://www.drugdevelopment-technology.com/news/newsdaiichi-sankyo-begins-phase-iii-trial-of-u3-1402-to-treat-breast-cancer-in-japan-5720107 http://www.drugdevelopment-technology.com/news/newsdaiichi-sankyo-begins-phase-iii-trial-of-u3-1402-to-treat-breast-cancer-in-japan-5720107 Japanese-based pharmaceutical company Daiichi Sankyo has begun its Phase I/II trial of U3-1402 to treat patients with HER3-positive metastatic or unresectable breast cancer in Japan. Fri, 20 Jan 2017 00:00:00 GMT Deals this week: Takeda Pharmaceutical, HUYA Bioscience International, Egalet http://www.drugdevelopment-technology.com/news/newsdeals-this-week-takeda-pharmaceutical-huya-bioscience-international-egalet-5720871 http://www.drugdevelopment-technology.com/news/newsdeals-this-week-takeda-pharmaceutical-huya-bioscience-international-egalet-5720871 Japanese pharmaceutical company Takeda Pharmaceutical has signed a global agreement with US-based bio-pharmaceutical company Ovid Therapeutics for clinical development and commercialisation of the former’s investigational new drug TAK-935. Fri, 20 Jan 2017 00:00:00 GMT UCB and Dermira report positive Phase III trial results of Cimzia to treat chronic plaque psoriasis http://www.drugdevelopment-technology.com/news/newsucb-and-dermira-report-positive-phase-iii-cimpact-trial-results-of-cimzia-to-treat-chronic-plaque-psoriasis-5720215 http://www.drugdevelopment-technology.com/news/newsucb-and-dermira-report-positive-phase-iii-cimpact-trial-results-of-cimzia-to-treat-chronic-plaque-psoriasis-5720215 UCB and Dermira have reported positive results from its Phase III CIMPACT trial of Cimzia (certolizumab pegol) to treat adult patients with moderate-to-severe chronic plaque psoriasis. Fri, 20 Jan 2017 00:00:00 GMT M&As this week: Malin Corporation, Eli Lilly and Company http://www.drugdevelopment-technology.com/news/newsmas-this-week-malin-corporation-eli-lilly-and-company-5720788 http://www.drugdevelopment-technology.com/news/newsmas-this-week-malin-corporation-eli-lilly-and-company-5720788 Irish life sciences company Malin Corporation has acquired 33% stake in Wren Therapeutics with the aim of developing rational therapeutic strategies. Fri, 20 Jan 2017 00:00:00 GMT Interface Clinical Research suggests new model for primary care clinical trials in UK http://www.drugdevelopment-technology.com/news/newsinterface-clinical-research-suggests-new-model-for-primary-care-clinical-trials-in-uk-5719335 http://www.drugdevelopment-technology.com/news/newsinterface-clinical-research-suggests-new-model-for-primary-care-clinical-trials-in-uk-5719335 UK-based clinical trials company Interface Clinical Research has suggested a new model to conduct primary care clinical trials following their launch at the Royal Society in London. Thu, 19 Jan 2017 00:00:00 GMT Protagonist Therapeutics initiates Phase IIb trial of PTG-100 to treat ulcerative colitis http://www.drugdevelopment-technology.com/news/newsprotagonist-therapeutics-starts-phase-iib-trial-of-ptg-100-to-treat-ulcerative-colitis-5718807 http://www.drugdevelopment-technology.com/news/newsprotagonist-therapeutics-starts-phase-iib-trial-of-ptg-100-to-treat-ulcerative-colitis-5718807 US-based clinical-stage biopharmaceutical company Protagonist Therapeutics has initiated its Phase IIb clinical trial of PTG-100 to treat ulcerative colitis. Thu, 19 Jan 2017 00:00:00 GMT SWOG to conduct immunotherapy clinical trial to treat rare cancers http://www.drugdevelopment-technology.com/news/newsswog-to-conduct-immunotherapy-clinical-trial-to-treat-rare-cancers-5719617 http://www.drugdevelopment-technology.com/news/newsswog-to-conduct-immunotherapy-clinical-trial-to-treat-rare-cancers-5719617 SWOG, a part of National Cancer Institute’s National Clinical Trials Network and the NCI Community Oncology Research Programme, has launched the DART immunotherapy trial of ipilimumab and nivolumab (Opdivo) to treat rare cancers. Thu, 19 Jan 2017 00:00:00 GMT New clinical trial to test drug combination to treat osteogenesis imperfecta http://www.drugdevelopment-technology.com/news/newsnew-clinical-trial-to-test-drug-combination-to-treat-osteogenesis-imperfecta-5719102 http://www.drugdevelopment-technology.com/news/newsnew-clinical-trial-to-test-drug-combination-to-treat-osteogenesis-imperfecta-5719102 The University of Edinburgh will conduct a six-year trial of teriparatide and zoledronic acid combination to treat a condition called osteogenesis imperfecta (OI). Wed, 18 Jan 2017 00:00:00 GMT Jazz Pharmaceuticals begins enrolment in Phase III trial of defitelio to treat VOD http://www.drugdevelopment-technology.com/news/newsjazz-pharmaceuticals-starts-enrolment-in-phase-iii-trial-of-defitelio-to-treat-vod-5718642 http://www.drugdevelopment-technology.com/news/newsjazz-pharmaceuticals-starts-enrolment-in-phase-iii-trial-of-defitelio-to-treat-vod-5718642 Ireland-based Jazz Pharmaceuticals has started patient enrolment in a Phase III clinical trial of defitelio (defibrotide sodium) against best supportive care (BSC) to address hepatic veno-occlusive disease (VOD) in adult and pediatric patients underg… Wed, 18 Jan 2017 00:00:00 GMT Allergan and Gedeon Richter report positive results from Venus II trial of ulipristal acetate http://www.drugdevelopment-technology.com/news/newsallergan-and-gedeon-richter-report-positive-results-from-venus-ii-trial-of-ulipristal-acetate-5718106 http://www.drugdevelopment-technology.com/news/newsallergan-and-gedeon-richter-report-positive-results-from-venus-ii-trial-of-ulipristal-acetate-5718106 Allergan and Gedeon Richter have reported positive results from Venus II, the second of two pivotal phase III clinical trials evaluating the efficacy and safety of ulipristal acetate in women with abnormal bleeding due to uterine fibroids. Wed, 18 Jan 2017 00:00:00 GMT BioLineRx begins Phase IIa trial of BL-8040 combined with KEYTRUDA to treat metastatic pancreatic cancer http://www.drugdevelopment-technology.com/news/newsbiolinerx-starts-phase-iia-trial-of-bl-8040-combined-with-keytruda-to-treat-metastatic-pancreatic-cancer-5718315 http://www.drugdevelopment-technology.com/news/newsbiolinerx-starts-phase-iia-trial-of-bl-8040-combined-with-keytruda-to-treat-metastatic-pancreatic-cancer-5718315 Clinical-stage bio-pharmaceutical company BioLineRx has begun its second Phase 2a trial investigating BL-8040 in combination with KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy, in patients suffering with metastatic pancreatic cancer. Tue, 17 Jan 2017 00:00:00 GMT Clinical study suggests efficacy of modafinil to improve memory in patients with depression http://www.drugdevelopment-technology.com/news/newsclinical-study-suggests-efficacy-of-modafinil-to-improve-memory-in-patients-with-depression-5717552 http://www.drugdevelopment-technology.com/news/newsclinical-study-suggests-efficacy-of-modafinil-to-improve-memory-in-patients-with-depression-5717552 A clinical study conducted by the University of Cambridge has suggested efficacy of the drug modafinil for improving memory in patients recovering from depression. Tue, 17 Jan 2017 00:00:00 GMT Chi-Med initiates Phase II study of sulfatinib to treat second-line biliary tract cancer in China http://www.drugdevelopment-technology.com/news/newschi-med-starts-phase-ii-study-of-sulfatinib-to-treat-second-line-biliary-tract-cancer-in-china-5716904 http://www.drugdevelopment-technology.com/news/newschi-med-starts-phase-ii-study-of-sulfatinib-to-treat-second-line-biliary-tract-cancer-in-china-5716904 Hutchison China MediTech (Chi-Med) has initiated its Phase II study by administering the first dose of sulfatinib to treat second-line biliary tract cancer (BTC) patients in China. Tue, 17 Jan 2017 00:00:00 GMT Tocagen commences Phase 2/3 clinical trial for recurrent brain cancer in South Korea http://www.drugdevelopment-technology.com/news/newstocagen-begins-enrolment-in-phase-iiiii-trial-of-toca-511-and-toca-fc-in-south-korea-5716538 http://www.drugdevelopment-technology.com/news/newstocagen-begins-enrolment-in-phase-iiiii-trial-of-toca-511-and-toca-fc-in-south-korea-5716538 Clinical-stage, cancer-selective gene therapy company Tocagen has announced its randomised, controlled Phase 2/3 clinical trial, Toca 5, has begun patient enrolment in South Korea. Mon, 16 Jan 2017 00:00:00 GMT